Loading stock data…
Vor Biopharma Inc (VOR)
$19.26+0.28 (+1.48%)
Market ClosedLast close Jul 24
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vor Biopharma Inc. in the Healthcare sector is trading at $19.26 with a market capitalization of $758M. Wall Street consensus targets $37.88 (8 analysts), implying a +96.7% move over the next 12 months. The stock is currently 64% below its 52-week high of $53.00, remaining 21.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +96.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$35.16M↑ | -$35.96M↓ | -$28.11M↑ | -$274.28M↓ | -$33.29M |
| Net Income | -$219.59M↓ | $1.72B↑ | -$812.68M↑ | -$1.57B↓ | -$32.49M |
Peer Comparison
JNJUNHPFE
Fundamentals
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$758.06M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
587.06%
Volume
Today's trading volume
616,581
Recent News
Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next
In late June 2026, Vor Biopharma Inc. was added to a broad suite of FTSE Russell indices, including the Russell 2000, 2500, 3000, Microcap, and related growth and value benchmarks. This sweeping inclusion across small-cap and microcap universes can expand Vor Biopharma’s visibility with institutional investors and passive index-tracking funds. We’ll now examine how this broad Russell index inclusion shapes Vor Biopharma’s investment narrative for investors assessing liquidity and...
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics.
We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade
The consensus price target hints at a 124.6% upside potential for Vor Biopharma (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.